Belotti, Angelo
University Medical Center Groningen · National and Kapodistrian University of Athens · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · St. Antonius Ziekenhuis · Erasmus MC Cancer Institute · Amsterdam University Medical Centers · University of Turin · Vrije Universiteit Amsterdam · Amsterdam UMC Location Vrije Universiteit Amsterdam
5 papers on CoChatORCID 0000-0002-0617-3127
Most cited papers
- Verified
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine
Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research
Cited by 599
- Verified
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksac, M., Katodritou, E., Moreau, P., Baldini, L., Symeonidis, A., Bila, J., et al. (2021) · The Lancet Oncology
Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research
Cited by 344
- Verified
Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: Kinetics of its appearance and potential predictive role in infectious complications
Belotti, A., Duca, L., Borin, L., Realini, S., Renso, R., Parma, M., Pioltelli, P., Pogliani, E., & Cappellini, M. D. (2015) · Leukemia Research
Iron Metabolism and DisordersAcute Myeloid Leukemia Research
Cited by 23
- Verified
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity
Sacco, A., Federico, C., Todoerti, K., Ziccheddu, B., Palermo, V., Giacomini, A., Ravelli, C., Maccarinelli, F., Bianchi, G., Belotti, A., et al. (2021) · Blood
Multiple Myeloma Research and TreatmentsAcute Myeloid Leukemia Research
Cited by 20
- Verified
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
Bruzzese, A., Derudas, D., Galli, M., Martino, E. A., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Farina, G., et al. (2022) · Hematological Oncology
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 17
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free